Stay updated on Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    Added several user assistance sections (How to Read a Study Record, Common Questions, How to Join a Study) and clarified the Intervention/Treatment header, improving navigation and clarity of what the study involves. The change also introduces a recruitment status note ('No longer looking for participants') and updates the page revision tag (from v3.5.5 to v3.6.0), reflecting an overall update to the study page.
    Difference
    0.5%
    Check dated 2026-06-12T12:41:32.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The page revision was updated from v3.5.4 to v3.5.5, representing a minor version update to the site's study record.
    Difference
    0.1%
    Check dated 2026-06-05T10:00:28.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    22 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    A new revision tag v3.5.4 was added, replacing the previous v3.5.3; this indicates an internal software or content-management update rather than a substantive change to the study information.
    Difference
    0.1%
    Check dated 2026-05-15T05:35:20.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    <div>Updates the page’s revision/version label from <code>v3.5.2</code> to <code>v3.5.3</code>.</div>
    Difference
    0.1%
    Check dated 2026-04-24T06:28:26.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T02:52:56.000Z thumbnail image
  8. Check
    79 days ago
    Change Detected
    Summary
    No substantive changes detected in core content; study details, eligibility criteria, and outcome measures appear unchanged.
    Difference
    0.1%
    Check dated 2026-03-26T12:14:51.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.